Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 6

Patient characteristics at initiation of TNF-α inhibitor therapy and at study inclusion.

	TNFi initiation			Study inclusion
	Anti-TNFi Ab			Anti-TNFi Ab
	Negative	Positive		Negative	Positive
Disease duration, years	10 (4–18)	2 (2–10)	0.027	15 (8–23)	8 (5–16)	0.045
Methotrexate, (%)	73 (87)	9 (100)	0.250	69 (82)	9 (100)	0.346
Methotrexate, mg/week	15 (7.5–20)	20 (20–22.5)	0.070	10 (7.5–15)	15 (7.5–15)	0.389
Glucocorticoid, (%)	18 (21)	2 (22)	0.979	4 (5)	0	0.506
Glucocorticoid, mg/day	0 (0)	0 (0)	0.822	0 (0)	0	0.993

Continuous variables are expressed as medians (interquartile ranges).